Cleveland State University

1m is a healthtech company that offers a software platform for risk management and performance improvement services.

Dyania Health is a company focused on enhancing clinical research through its proprietary Synapsis AI platform. The platform automates manual chart review, a traditionally inefficient and time-consuming process in healthcare, allowing clinicians to provide optimal care when it is most needed. Dyania's technology is utilized by large healthcare systems to streamline enterprise-wide clinical trial pre-screening, conduct automated chart reviews for observational studies, and facilitate complex registry reporting. By leveraging artificial intelligence and machine learning, the platform efficiently analyzes unstructured electronic medical record data to identify potential candidates for clinical drug trials, ultimately improving the productivity and efficiency of clinical research teams while ensuring more accurate and timely patient care.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

Strolll is a digital health startup focused on enhancing mobility for individuals with neurological disorders. The company develops extended reality digital therapeutics that empower movement therapy through innovative solutions. By integrating augmented reality services into its offerings, Strolll provides cueing therapy and gamified exercise programs aimed at improving gait and balance. These therapies are specifically designed to reduce fall risk for patients with conditions such as Parkinson's disease, enabling them to better manage their symptoms and improve their overall quality of life.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Enspire DBS Therapy, Inc. is a Cleveland, Ohio-based company focused on developing a proprietary deep brain stimulation (DBS) therapy aimed at restoring motor function in stroke survivors living with disabilities. Founded in 2010, the company is engaged in clinical trials to evaluate the effectiveness of its DBS therapy in enhancing stroke recovery. Its innovative approach combines deep brain stimulation with physical rehabilitation, utilizing natural pathways to optimize outcomes for patients. By facilitating accelerated post-stroke recovery, Enspire DBS Therapy aims to improve the quality of life for individuals affected by stroke-related motor impairments.

MediView, LLC is a medical device company based in Cleveland, Ohio, that specializes in developing augmented reality surgical navigation systems aimed at enhancing surgical processes for healthcare providers. Founded in 2017, the company focuses on creating advanced technologies for surgical navigation, particularly for the ablation and biopsy of cancerous tumors. MediView's flagship product, MediView, utilizes real-time, fused-holographic visualization to enable surgeons to navigate procedures with greater accuracy and efficacy. This innovative approach allows for enhanced examination of patients through augmented reality 3D visualization, facilitating improved surgical outcomes and supporting remote collaboration among healthcare professionals.

Centerline Biomedical, Inc. is a Cleveland, Ohio-based company founded in 2014 that specializes in developing advanced surgical navigation technologies. The company focuses on an Intra-Operative Positioning System, which utilizes non-x-ray based three-dimensional GPS technology to enhance the precision of endovascular procedures and minimize radiation exposure for both patients and medical staff. Centerline's innovative system aids surgeons in navigating complex three-dimensional vascular anatomy, thereby improving surgical outcomes in interventional vascular procedures. The technology is rooted in advancements made at the Cleveland Clinic, reflecting a commitment to enhancing the safety and effectiveness of minimally invasive surgeries.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

Xealth Inc. is a digital health company that has developed a comprehensive platform enabling clinicians to integrate, prescribe, and monitor various digital health tools and programs directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, Xealth's platform allows care teams to efficiently order digital health solutions for patients, facilitating seamless communication through email or patient portals. The platform also provides functionality for monitoring patient engagement and analyzing the impact of these tools on patient outcomes. Additionally, Xealth supports non-clinical services, such as ride-sharing and food delivery, enhancing the overall patient experience and promoting greater utilization of digital health resources.

Cleveland Diagnostics is a commercial-stage company based in Cleveland, Ohio, focused on developing and commercializing innovative cancer diagnostic tests. Founded in 2013, the company specializes in creating non-invasive screening tools for various cancers, including prostate, breast, ovarian, lung, and certain neurological diseases. Their portfolio includes blood-based tests designed to enhance early detection and improve patient outcomes. Cleveland Diagnostics employs a proprietary solvent interaction analysis technology that examines protein biomarkers at a structural level, offering more precise insights into disease processes and enhancing test specificity. The company has established strategic collaborations with industry partners, such as Genomic Health, to advance its diagnostic capabilities.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Cardionomic, Inc. is a medical device company focused on developing a catheter-based therapy for acute decompensated heart failure (ADHF). Founded in 2007 and headquartered in New Brighton, Minnesota, Cardionomic's innovative technology utilizes neuromodulation to electrically stimulate cardiac nerves, addressing the underlying issue of reduced cardiac output. The device is inserted into the right pulmonary artery via the internal jugular vein, where it selectively stimulates autonomic nerves to enhance ventricular contractility without impacting heart rate. This approach aims to improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Additionally, the therapy helps reduce levels of plasma norepinephrine and B-type natriuretic peptide, which are key biomarkers associated with chronic heart failure. By targeting the root cause of ADHF, Cardionomic seeks to enhance patient outcomes and reduce complications in healthcare settings.

Advanced NanoTherapies, Inc. is a biotechnology company focused on developing innovative medical devices utilizing Sirolimus and biodegradable functionalized nanoparticle technology for the treatment of atherosclerosis and related conditions, including coronary artery disease and peripheral artery disease. Founded in 2018, the company is headquartered in Cleveland, Ohio. Advanced NanoTherapies aims to enhance drug delivery through its proprietary platform, which improves medication uptake and retention at the cellular level. This technology provides clinicians with safer treatment options for patients suffering from cardiovascular and endovascular diseases.

Xealth Inc. is a digital health company that has developed a comprehensive platform enabling clinicians to integrate, prescribe, and monitor various digital health tools and programs directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, Xealth's platform allows care teams to efficiently order digital health solutions for patients, facilitating seamless communication through email or patient portals. The platform also provides functionality for monitoring patient engagement and analyzing the impact of these tools on patient outcomes. Additionally, Xealth supports non-clinical services, such as ride-sharing and food delivery, enhancing the overall patient experience and promoting greater utilization of digital health resources.

Indian River Medical Center is a 332-bed hospital located in Florida, dedicated to delivering exceptional, patient-centered, and evidence-based healthcare to the residents of Indian River County and surrounding areas. The facility features a comprehensive range of services, including an emergency department, bariatric services, pediatrics, gynecology, gastroenterology, neuroscience, cardiology, diabetes care, and a behavioral health center. By focusing on the diverse healthcare needs of the community, Indian River Medical Center aims to provide high-quality medical services and improve health outcomes for its patients.

Martin Health System comprises three hospitals, one Urgent Care Center, a free-standing emergency center and numerous centers and clinics. We are dedicated to providing exceptional health care, hope and compassion to the citizens of Florida’s Treasure Coast region (which encompasses Stuart, Jensen Beach, Hobe Sound, Palm City and Port St. Lucie).

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, specializing in innovative solutions for patients with congestive heart failure. Founded in 2011, the company has developed the V-LAP, the first in-heart microcomputer designed to enhance treatment for heart failure patients by facilitating daily monitoring of left atrial pressure (LAP). This miniature wireless implant is a groundbreaking device that operates without batteries and can transmit data from deep within the body, offering a reliable means of detecting potential deterioration in heart failure. The V-LAP has been recognized as an effective predictor of heart failure worsening, thereby improving patients' quality of life and life expectancy. Vectorious is currently conducting clinical studies in various European countries, including Italy, Germany, and the UK, to obtain regulatory approval, with plans to initiate a clinical study in the United States.

Hemex Health, Inc. specializes in developing and manufacturing medical diagnostic devices aimed at populations at risk for malaria and sickle cell disease. Founded in 2016 and based in Portland, Oregon, the company offers innovative products such as the Magneto-Optical Device (MOD), which detects all strains of malaria in under a minute, and the HemeChip, designed to identify hemoglobin disorders. Additionally, Hemex Health provides the SMART solution for early detection of sickle cell disease and malaria through point-of-care testing, enabling healthcare professionals in both clinical and field settings to deliver rapid and affordable diagnostics. The company's portable devices allow physicians, small laboratories, and frontline healthcare workers to diagnose and treat these diseases more efficiently, thereby improving patient outcomes in underserved regions.

Cardionomic, Inc. is a medical device company focused on developing a catheter-based therapy for acute decompensated heart failure (ADHF). Founded in 2007 and headquartered in New Brighton, Minnesota, Cardionomic's innovative technology utilizes neuromodulation to electrically stimulate cardiac nerves, addressing the underlying issue of reduced cardiac output. The device is inserted into the right pulmonary artery via the internal jugular vein, where it selectively stimulates autonomic nerves to enhance ventricular contractility without impacting heart rate. This approach aims to improve cardiac output, renal blood flow, urine production, and pharmacological tolerance. Additionally, the therapy helps reduce levels of plasma norepinephrine and B-type natriuretic peptide, which are key biomarkers associated with chronic heart failure. By targeting the root cause of ADHF, Cardionomic seeks to enhance patient outcomes and reduce complications in healthcare settings.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Ascent is a national tele-health provider of certified addiction support services that uses artificial intelligence to predict impending relapse and deliver proactive coach led interventions. The service provides value add for end users by being delivered through its integrated chronic disease management platform by Sober Grid, Inc The Sober Grid app has been studied by researchers who have identified that there is a correlation with the use of the Sober Grid app and lower relapse rates. Ascent powered by Sober Grid's clients include municipal governments, insurance companies managed care organizations, drug courts, health care providers, hospitals, and treatment clinics in the United States. Ascent employs a staff of state certified addiction recovery coaches to provide on demand and scheduled sessions. Coaches are staffed 24/7/365. Coaches can be accessed via scheduled meetings or on -demand as crisis management. Available anytime, anywhere the low cost support democratizes addiction support while eliminating traditional barriers to accessing support such as access to transportation, rural settings, fear of stigma, and scheduling conflicts. All coaches are trained and certified by a state government in both addiction and mental health. Coaches adhere to the critical philosophy of multiple pathways of recovery. Coaches all have lived experience and have related real life experience and have successfully stayed in remission from acute symptoms of relapsing for a number of years.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

Explorys, Inc. is a healthcare cloud-computing company based in Cleveland, Ohio, founded in 2009. It specializes in providing a comprehensive platform for enterprise performance management tailored to integrated healthcare systems across the United States. The platform facilitates data management, business intelligence, and population analytics, allowing healthcare organizations to identify patterns in diseases, treatments, and outcomes. By enabling the collection and integration of diverse data types—including clinical, claims, billing, and patient information—Explorys supports healthcare providers, payers, and life sciences organizations in improving care quality and operational efficiency. Additionally, the platform aids in enhancing research capabilities and accelerating product development within the healthcare sector. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.

Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.

Complient Corporation, based in Cleveland, is the nation's premier provider of AED programs and actively manages hundreds of corporate and government AED programs representing more than 3,000 AED devices. Complient trains lay people to save lives and prepares them to respond to commonplace medical emergencies. To date, over 250,000 individuals have been trained on AED operation and CPR by its 150 dedicated full- and part-time trainers on staff covering all 50 states in the United States. Since its inception in 1997, over $50 million in equity venture capital has been invested to develop Complient's web-based technology infrastructure and AED program management service business. For more information, visit www.complient.com.